We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Forma Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics with rare hematologic diseases and cancers. Forma Therapeutics Holdings Inc. is based in Watertown, United States.
- Recent FMTX Stock Price: $19.98
- Yearly Gain for FMTX stock: -14.76%
- Market Cap for FMTX stock: $956.09M
- P/E Ratio for FMTX stock: -4.994
Will FMTX's stock price go up? Is there an accurate FMTX stock forecast available?
TipRanks.com reports that Forma Therapeutics Holdings currently has 6 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $20.60. The target pricing ranges from a high FMTX forecast of $23.00 down to a low forecast of $20.00. Forma Therapeutics Holdings (FMTX)’s last closing stock price was $19.98 which would put the average price target at 3.10% upside.
In addition, TradingView issued a Buy rating for FMTX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on FMTX stock.
Other analysts covering FMTX include:
- Tiago Fauth of Credit Suisse issued a Hold rating with the price target of $ 20 on 1 day ago
- Robert Burns of H.C. Wainwright issued a Hold rating with the price target of $ 20 on 1 day ago
- Prakhar Agrawal of Cantor Fitzgerald issued a Hold rating with the price target of $ 20 on 2 days ago
If you are wondering if FMTX is a good stock to buy, here are 3rd party ratings for FMTX stock:
- TipRanks.com: Hold
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 25% (63 out of 252)
What is the sentiment on the street regarding Forma Therapeutics Holdings? (Current ratings compiled by TipRanks.com)
- News Sentiment for FMTX stock: Very Bullish
- Blogger Consensus for FMTX stock: n/a
- Media Buzz for FMTX stock: High
- Insider Signal for FMTX stock: n/a
- Investor Sentiment for FMTX stock: Very Positive
- Hedge Fund signal for FMTX stock: Neutral
The stock market is extremely volatile, and you need to do your own research on FMTX stock including scouring the social networks like FMTX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for FMTX stock chart >>
Summary: Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States.
- Recent ALT Stock Price: $22.41
- Yearly Gain for ALT stock: 36.40%
- Market Cap for ALT stock: $1.10B
- P/E Ratio for ALT stock: -9.968
Will ALT's stock price go up? Is there an accurate ALT stock forecast available?
TipRanks.com reports that Altimmune currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is 32.50. The target pricing ranges from a high ALT forecast of $50.00 down to a low forecast of $25.00. Altimmune (ALT)’s last closing stock price was $22.41 which would put the average price target at 45.02% upside.
In addition, TradingView issued a Buy rating for ALT stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ALT stock.
Other analysts covering ALT include:
- Roger Song of Jefferies issued a Buy rating with the price target of $ 35 on 3 days ago
- Mayank Mamtani of B.Riley Financial issued a Buy rating with the price target of $ 26 on 3 days ago
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $ 25 on 4 days ago
- Patrick Trucchio of H.C. Wainwright issued a Buy rating with the price target of $ 50 on 2 weeks ago
If you are wondering if ALT is a good stock to buy, here are 3rd party ratings for ALT stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 29% (74 out of 252)
What is the sentiment on the street regarding Altimmune? (Current ratings compiled by TipRanks.com)
- News Sentiment for ALT stock: Very Bullish
- Blogger Consensus for ALT stock: Bullish
- Media Buzz for ALT stock: Medium
- Insider Signal for ALT stock: Positive
- Investor Sentiment for ALT stock: Very Positive
- Hedge Fund signal for ALT stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on ALT stock including scouring the social networks like ALT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ALT stock chart >>
Summary: Patterson Companies Inc. is one of the leading distributors of dental and animal health products. It has 3 segments: Dental, Animal Health and Corporate. Dental segment distributes consumable products, basic & advanced technology dental equipment, practice management & clinical software, patient education systems, and office forms and stationery in the U.S. & Canada. Its customers include dentists, dental laboratories, institutions, and other healthcare professionals. This unit is also the exclusive distributor for Sirona Dental Systems, a leading dental technologies company. Animal Health unit is a leading distributor of veterinary supplies to companion-pet veterinary clinics, equine and large animal veterinary clinics, public and private institutions, and shelters across the U.S. It acquired Animal Health International. Corporate segment comprises general and administrative expenses, including home office support costs in areas such as information technology, finance, legal, human resources and facilities.
- Recent PDCO Stock Price: $25.35
- Yearly Gain for PDCO stock: -15.44%
- Market Cap for PDCO stock: $2.45B
- P/E Ratio for PDCO stock: 13.263
Will PDCO's stock price go up? Is there an accurate PDCO stock forecast available?
TipRanks.com reports that Patterson Companies currently has 6 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $34.25. The target pricing ranges from a high PDCO forecast of $40.00 down to a low forecast of $26.50. Patterson Companies (PDCO)’s last closing stock price was $25.35 which would put the average price target at 35.11% upside.
In addition, TradingView issued a Strong Sell rating for PDCO stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on PDCO stock.
Other analysts covering PDCO include:
- Jason Bednar of Piper Sandler issued a Buy rating with the price target of $ 40 on 2 days ago
- Elizabeth Anderson CFA of Evercore ISI issued a Hold rating with the price target of $ 26.5 on 2 days ago
- Jeff Johnson of Robert W. Baird issued a Hold rating with the price target of $ 35 on 1 month ago
- A.J. Rice of Credit Suisse issued a Buy rating with the price target of $ 37 on 2 months ago
If you are wondering if PDCO is a good stock to buy, here are 3rd party ratings for PDCO stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 24% (191 out of 252)
What is the sentiment on the street regarding Patterson Companies? (Current ratings compiled by TipRanks.com)
- News Sentiment for PDCO stock: Neutral
- Blogger Consensus for PDCO stock: Bullish
- Media Buzz for PDCO stock: Very Low
- Insider Signal for PDCO stock: n/a
- Investor Sentiment for PDCO stock: Very Positive
- Hedge Fund signal for PDCO stock: Negative
The stock market is extremely volatile, and you need to do your own research on PDCO stock including scouring the social networks like PDCO StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for PDCO stock chart >>
Summary: The Cooper Companies Inc, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision and CooperSurgical. CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company's products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness.'CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians.
- Recent COO Stock Price: $295.53
- Yearly Gain for COO stock: -35.17%
- Market Cap for COO stock: $14.58B
- P/E Ratio for COO stock: 34.053
Will COO's stock price go up? Is there an accurate COO stock forecast available?
TipRanks.com reports that Cooper Co currently has 9 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $370.71. The target pricing ranges from a high COO forecast of $460.00 down to a low forecast of $300.00. Cooper Co (COO)’s last closing stock price was $295.53 which would put the average price target at 20.40% upside.
In addition, TradingView issued a Sell rating for COO stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on COO stock.
Other analysts covering COO include:
- Larry Biegelsen of Wells Fargo issued a Buy rating with the price target of $ 365 on 2 days ago
- Joanne Wuensch of Citigroup issued a Buy rating with the price target of $ 350 on 2 days ago
- Robbie Marcus of J.P. Morgan issued a Hold rating with the price target of $ 300 on 2 days ago
If you are wondering if COO is a good stock to buy, here are 3rd party ratings for COO stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Bottom 24% (191 out of 252)
What is the sentiment on the street regarding Cooper Co? (Current ratings compiled by TipRanks.com)
- News Sentiment for COO stock: Neutral
- Blogger Consensus for COO stock: Bullish
- Media Buzz for COO stock: Very Low
- Insider Signal for COO stock: n/a
- Investor Sentiment for COO stock: Very Positive
- Hedge Fund signal for COO stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on COO stock including scouring the social networks like COO StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for COO stock chart >>
Summary: Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States.
- Recent LQDA Stock Price: $5.86
- Yearly Gain for LQDA stock: 113.87%
- Market Cap for LQDA stock: $377.16M
- P/E Ratio for LQDA stock: -7.174
Will LQDA's stock price go up? Is there an accurate LQDA stock forecast available?
TipRanks.com reports that Liquidia Technologies currently has 6 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $14.00. The target pricing ranges from a high LQDA forecast of $20.00 down to a low forecast of $3.00. Liquidia Technologies (LQDA)’s last closing stock price was $5.86 which would put the average price target at 138.91% upside.
In addition, TradingView issued a Neutral rating for LQDA stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on LQDA stock.
Other analysts covering LQDA include:
- Liana Moussatos of Wedbush issued a Sell rating with the price target of $ 3 on 2 days ago
- Julian Harrison of BTIG issued a Buy rating with the price target of $ 20 on 3 days ago
- Matthew Kaplan of Ladenburg Thalmann & Co. issued a Buy rating with the price target of $ 15 on 3 days ago
- Andrew Fein of H.C. Wainwright issued a Buy rating with the price target of $ 16 on 3 days ago
If you are wondering if LQDA is a good stock to buy, here are 3rd party ratings for LQDA stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 25% (63 out of 252)
What is the sentiment on the street regarding Liquidia Technologies? (Current ratings compiled by TipRanks.com)
- News Sentiment for LQDA stock: Very Bullish
- Blogger Consensus for LQDA stock: n/a
- Media Buzz for LQDA stock: Very High
- Insider Signal for LQDA stock: Positive
- Investor Sentiment for LQDA stock: Very Positive
- Hedge Fund signal for LQDA stock: Neutral
The stock market is extremely volatile, and you need to do your own research on LQDA stock including scouring the social networks like LQDA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for LQDA stock chart >>
Summary: Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-' agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.
- Recent MDGL Stock Price: $71.71
- Yearly Gain for MDGL stock: -11.21%
- Market Cap for MDGL stock: $1.23B
- P/E Ratio for MDGL stock: -4.758
Will MDGL's stock price go up? Is there an accurate MDGL stock forecast available?
TipRanks.com reports that Madrigal Pharmaceuticals currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $141.00. The target pricing ranges from a high MDGL forecast of $180.00 down to a low forecast of $75.00. Madrigal Pharmaceuticals (MDGL)’s last closing stock price was $71.71 which would put the average price target at 96.63% upside.
In addition, TradingView issued a Buy rating for MDGL stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MDGL stock.
Other analysts covering MDGL include:
- Jonathan Wolleben of JMP Securities issued a Buy rating with the price target of $ 180 on 3 days ago
- Mayank Mamtani of B.Riley Financial issued a Hold rating with the price target of $ 75 on 1 month ago
- Edward Nash of Canaccord Genuity issued a Buy rating with the price target of $ 151 on 2 months ago
If you are wondering if MDGL is a good stock to buy, here are 3rd party ratings for MDGL stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 29% (74 out of 252)
What is the sentiment on the street regarding Madrigal Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for MDGL stock: Very Bullish
- Blogger Consensus for MDGL stock: Bullish
- Media Buzz for MDGL stock: Very High
- Insider Signal for MDGL stock: n/a
- Investor Sentiment for MDGL stock: Very Positive
- Hedge Fund signal for MDGL stock: Neutral
The stock market is extremely volatile, and you need to do your own research on MDGL stock including scouring the social networks like MDGL StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MDGL stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
